DMAC vs. RPTX, PDSB, SGMT, SYRS, FGEN, ACET, AMLX, NVCT, RGLS, and INCR
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Repare Therapeutics (RPTX), PDS Biotechnology (PDSB), Sagimet Biosciences (SGMT), Syros Pharmaceuticals (SYRS), FibroGen (FGEN), Adicet Bio (ACET), Amylyx Pharmaceuticals (AMLX), Nuvectis Pharma (NVCT), Regulus Therapeutics (RGLS), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry.
Repare Therapeutics (NASDAQ:RPTX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
DiaMedica Therapeutics received 56 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 62.07% of users gave DiaMedica Therapeutics an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
Repare Therapeutics presently has a consensus target price of $17.33, suggesting a potential upside of 389.64%. DiaMedica Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 118.75%. Given DiaMedica Therapeutics' higher probable upside, equities analysts clearly believe Repare Therapeutics is more favorable than DiaMedica Therapeutics.
85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 28.5% of Repare Therapeutics shares are owned by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Repare Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
DiaMedica Therapeutics has a net margin of 0.00% compared to DiaMedica Therapeutics' net margin of -183.43%. DiaMedica Therapeutics' return on equity of -39.82% beat Repare Therapeutics' return on equity.
DiaMedica Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Repare Therapeutics had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Repare Therapeutics and 3 mentions for DiaMedica Therapeutics. Repare Therapeutics' average media sentiment score of 1.06 beat DiaMedica Therapeutics' score of 0.60 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.
Summary
Repare Therapeutics beats DiaMedica Therapeutics on 9 of the 16 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
